SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: The Board considers the existence of an efficient share-related, time and share price performance-based, incentive program for senior executives, other employees and key persons to be of material importance to the growth of Aerocrine. The proposed program is aimed at creating a common focus for participating employees and partners in various divisions of Aerocrine. Furthermore, the proposed program is part of Aerocrine’s strategy to build and strengthen the company’s U.S. operations and commercial organization, including the recent recruitment of Scott Myers as the new CEO. It is also in light of this strategy the terms of the proposed program should be seen. It is deemed necessary to create an incentive program with terms and conditions that are perceived as being competitive with those U.S. employers typically offer so as to enable appropriate recruitment in the United States and thereby continue the development of Aerocrine’s U.S. operations. The importance of this is underlined by the recent release of ATS (American Thoracic Society) clinical practice guidelines which strongly recommend the use of Aerocrine’s method in the treatment of asthma. The Board is of the opinion that the proposed program is vital to the attraction of Aerocrine as an employer and partner, both in the United States and elsewhere, thereby facilitating the recruitment and retention of key persons who will be important to the continued growth of Aerocrine and to maximize the shareholder value.
